LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
IPO Year:
Exchange: NASDAQ
Website: livanova.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/20/2024 | Buy | Needham | |
2/20/2024 | $60.00 → $70.00 | Neutral → Buy | Mizuho |
9/6/2023 | $52.00 | Hold | HSBC Securities |
7/19/2023 | $56.00 | Neutral | Robert W. Baird |
4/14/2023 | $48.00 | Neutral | Mizuho |
12/21/2022 | $62.00 | Equal Weight | Barclays |
4/6/2022 | $95.00 | Outperform | Wolfe Research |
2/24/2022 | $96.00 | Neutral → Buy | UBS |
2/24/2022 | $120.00 → $106.00 | Buy | Needham |
12/3/2021 | $108.00 | Buy | Goldman Sachs |
Needham reiterated coverage of LivaNova with a rating of Buy
Mizuho upgraded LivaNova from Neutral to Buy and set a new price target of $70.00 from $60.00 previously
HSBC Securities initiated coverage of LivaNova with a rating of Hold and set a new price target of $52.00
Robert W. Baird initiated coverage of LivaNova with a rating of Neutral and set a new price target of $56.00
Mizuho initiated coverage of LivaNova with a rating of Neutral and set a new price target of $48.00
Barclays initiated coverage of LivaNova with a rating of Equal Weight and set a new price target of $62.00
Wolfe Research initiated coverage of LivaNova with a rating of Outperform and set a new price target of $95.00
UBS upgraded LivaNova from Neutral to Buy and set a new price target of $96.00
Needham reiterated coverage of LivaNova with a rating of Buy and set a new price target of $106.00 from $120.00 previously
Goldman Sachs initiated coverage of LivaNova with a rating of Buy and set a new price target of $108.00
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights(1) Second-quarter revenue of $318.6 million increased 8.4% on a reported basis and 9.6% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 10.8% on a constant-currency basis. Second-quarter U.S. GAAP diluted earnings per share of $0.30 and adjusted diluted earnings per share of $0.93. Franco Poletti named President of Ca
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its second-quarter 2024 results prior to the call. A live audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 926038. A replay will be available on t
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights(1) First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 13.5% on a constant-currency basis First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73 Closed private offering of $345.0 milli
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2024 results prior to the call. A live audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 556837. A replay will be available on the L
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the quarter and full year ended December 31, 2023 and issued guidance for 2024. Financial Summary and Highlights1 Fourth-quarter revenue of $310.1 million increased 12.8 percent on a reported basis and 11.9 percent on a constant-currency basis, as compared to the prior-year period Fourth-quarter U.S. GAAP diluted earnings per share was $0.30 and adjusted diluted earnings per share was $0.87 Full-year 2023 revenue of $1.15 billion increased 12.9 percent on a reported basis and increased 13.3 percent on a constant-currency basis, as compared to the prior-year period Full-year 2023
Move Reinforces Focus on Core Cardiopulmonary and Neuromodulation Businesses ACS Standalone Cannulae Products and Accessories to Transition Into Cardiopulmonary Business Unit LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that it will commence immediately with an orderly wind down of the Advanced Circulatory Support (ACS) Business Unit to increase the Company's strategic focus on its core Cardiopulmonary (CP) and Neuromodulation Business Units. ACS generated approximately 4% of net revenue for the nine months ended September 30, 2023. The wind down is anticipated to be complete by the end of 2024. The Company will retain all ACS standalone can
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2023 results on Wednesday, February 21, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2023 results prior to the call. A live audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 206069.
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2023 and raised full-year 2023 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights1 Third-quarter revenue of $286.1 million increased 13.3% on a reported basis and increased 12.1% on a constant-currency basis, as compared to the prior-year period Third-quarter U.S. GAAP diluted loss per share was $0.14 and adjusted diluted earnings per share was $0.73 Received U.S. FDA 510(k) clearance and CE Mark for its EssenzTM In-Line Blood Monitor "LivaNova delivered double-digit revenue growth across all regions, improv
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2023 results on Wednesday, November 1, 2023 at 12 p.m. London time (8 a.m. Eastern Time). The Company will release its third-quarter 2023 results prior to the call. A live audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 951660. A replay will be available on
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2023 and raised full-year 2023 guidance. Financial Summary and Highlights1 Second-quarter revenue of $293.9 million increased 15.6% on a reported basis and increased 16.4% on a constant-currency basis, as compared to the prior-year period Second quarter U.S. GAAP diluted earnings per share was $0.02 and adjusted diluted earnings per share was $0.78 Randomized 150th bipolar depression patient in RECOVER clinical study and initiated interim analyses Effective May 12, Stephanie Bolton named President of Global Epilepsy following 12 years of LivaNova se
IRANNOTICE - LivaNova PLC (0001639691) (Filer)
10-Q - LivaNova PLC (0001639691) (Filer)
8-K - LivaNova PLC (0001639691) (Filer)
8-K - LivaNova PLC (0001639691) (Filer)
DEFA14A - LivaNova PLC (0001639691) (Filer)
144 - LivaNova PLC (0001639691) (Subject)
IRANNOTICE - LivaNova PLC (0001639691) (Filer)
10-Q - LivaNova PLC (0001639691) (Filer)
8-K - LivaNova PLC (0001639691) (Filer)
ARS - LivaNova PLC (0001639691) (Filer)
SC 13G - LivaNova PLC (0001639691) (Subject)
SC 13G/A - LivaNova PLC (0001639691) (Subject)
SC 13G/A - LivaNova PLC (0001639691) (Subject)
SC 13G/A - LivaNova PLC (0001639691) (Subject)
SC 13G/A - LivaNova PLC (0001639691) (Subject)
SC 13G/A - LivaNova PLC (0001639691) (Subject)
SC 13G/A - LivaNova PLC (0001639691) (Subject)
SC 13G/A - LivaNova PLC (0001639691) (Subject)
SC 13G/A - LivaNova PLC (0001639691) (Subject)
SC 13G/A - LivaNova PLC (0001639691) (Subject)
3 - LivaNova PLC (0001639691) (Issuer)
4 - LivaNova PLC (0001639691) (Issuer)
4 - LivaNova PLC (0001639691) (Issuer)
4 - LivaNova PLC (0001639691) (Issuer)
4 - LivaNova PLC (0001639691) (Issuer)
4 - LivaNova PLC (0001639691) (Issuer)
4 - LivaNova PLC (0001639691) (Issuer)
4 - LivaNova PLC (0001639691) (Issuer)
4 - LivaNova PLC (0001639691) (Issuer)
4 - LivaNova PLC (0001639691) (Issuer)
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Baird 2024 Global Healthcare Conference in New York. The presentation will take place at 10:15 a.m. Eastern Time on Tuesday, September 10. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the webcast. A replay will be available on the LivaNova website within 24 hours after the live presentation for 90 days after the event. About L
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights(1) Second-quarter revenue of $318.6 million increased 8.4% on a reported basis and 9.6% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 10.8% on a constant-currency basis. Second-quarter U.S. GAAP diluted earnings per share of $0.30 and adjusted diluted earnings per share of $0.93. Franco Poletti named President of Ca
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its second-quarter 2024 results prior to the call. A live audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 926038. A replay will be available on t
Primary endpoint did not achieve statistical significance in unipolar patient cohort Statistically significant and clinically meaningful benefits seen in select secondary endpoints; no safety concerns identified LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced the preliminary results for the unipolar patient cohort of the RECOVER clinical study, assessing the use of VNS Therapy™ in treatment-resistant depression. The study did not meet its primary endpoint (PE) for the unipolar cohort; however, statistical significance was achieved in select secondary endpoints. The PE measured the difference between active and sham VNS Therapy on the rate of Mo
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Goldman Sachs Healthcare Conference in Miami, Florida. The presentation will take place at 1:20 p.m. Eastern Time on Monday, June 10. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the webcast. A replay will be available on the LivaNova website within 24 hours after the live presentation for 90 days after the event. About LivaNo
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights(1) First-quarter revenue of $294.9 million increased 12.0% on a reported basis and 12.4% on a constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (ACS) segment wind down, revenue increased 13.5% on a constant-currency basis First-quarter U.S. GAAP diluted loss per share was $0.78 and adjusted diluted earnings per share was $0.73 Closed private offering of $345.0 milli
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024. In this newly created position, Tezel will leverage his career of more than 20 years in research and development (R&D) to establish an integrated innovation function at LivaNova that will accelerate the Company's development of new technologies. In this capacity, Tezel will join the LivaNova Executive Leadership Team. "I am very pleased to welcome Ahmet to the LivaNova team. At LivaNova, our commitment to pioneering innovation remains unwavering, and Ahmet's arrival marks a significant step in advanci
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that its wholly-owned U.S. subsidiary, LivaNova USA, Inc., is providing notice to U.S. patients regarding a cybersecurity incident that was initially disclosed by the Company on November 20, 2023. The incident resulted in a disruption to portions of the Company's information technology systems. Promptly after detecting the issue on November 19, 2023, LivaNova began an investigation with assistance from external cybersecurity experts and coordinated with law enforcement. The Company took action to remediate the issue, such as taking certain systems offline, and resumed manufacturing as previously discl
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2024 results on Wednesday, May 1, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2024 results prior to the call. A live audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen to the conference call by telephone, dial +1 833 470 1428 (if dialing from within the U.S.) or +1 929 526 1599 (if dialing from outside the U.S.). The conference call access code is 556837. A replay will be available on the L
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced its OSPREY clinical study, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation, has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated. This means there is a greater than 97.5% probability that the OSPREY trial will successfully meet its primary endpoint. OSPREY is a prospective, multi-center, randomized controlled open-label trial demonstrating the safety and effectiveness of the aura6000™ Hypoglossal Nerve Stimulator System versus a no stimulation control in subjects with moderate to severe obstructive sleep apnea (OSA) who have faile
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer (CINO), effective May 13, 2024. In this newly created position, Tezel will leverage his career of more than 20 years in research and development (R&D) to establish an integrated innovation function at LivaNova that will accelerate the Company's development of new technologies. In this capacity, Tezel will join the LivaNova Executive Leadership Team. "I am very pleased to welcome Ahmet to the LivaNova team. At LivaNova, our commitment to pioneering innovation remains unwavering, and Ahmet's arrival marks a significant step in advanci
Long-time Director Andrea Saia to retire from the Board LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today. Barry will serve on the Audit and Compliance Committee. Andrea Saia, who has served as a Director since 2016, will retire from the LivaNova Board on December 31, 2023. "The LivaNova Board of Directors is pleased to welcome Chris Barry," said Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova. "Chris has spent his career in the medical technology industry, and we look forward to adding his commercial expertise and ability to drive long-term gro
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Marco Dolci intends to retire as President of the Cardiopulmonary (CP) Business Unit (BU) by December 31, 2023. Dolci will continue in his role and support the transition of responsibilities through the end of the year. Franco Poletti will serve as Interim General Manager of CP to support the transition efforts, in addition to his current role as Vice President of CP for Europe, effective immediately. LivaNova will retain a leading international executive search firm to assist with the search for a permanent successor for the President of CP. "On behalf of the Board, the executive leadership team
Mechelen, Belgium; 15 June 2023, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced the appointment of Thad Huston as Chief Financial Officer (CFO) and Chief Operating Officer (COO) as per 1 July 2023. Mr. Huston will be a member of the Executive Committee of Galapagos and will join Galapagos from Kite, a Gilead Company (NASDAQ:GILD). He brings 30 years of global finance and operational experience in healthcare with an excellent track record of driving business transformation and innovation. "On behalf of the Board of Directors and management of Galapagos, I extend a warm welcome to Thad. Thad is a widely recognized leader with a strong internationa
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the LivaNova Board of Directors appointed Brooke Story to the Board, effective September 15, 2022. In addition, Story will be a member of the Nominating and Corporate Governance Committee of the Board. Story joins the LivaNova Board with more than 20 years of experience in the global medical technology industry. She currently serves as Worldwide President, Integrated Diagnostic Solutions at BD (Becton, Dickinson and Company) a position she assumed in April 2021. Prior to that, she spent 15 years at Medtronic, where she held a variety of roles in finance, sales and business unit leader
NEWTOWN, Pa., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced the appointment of Paul Buckman to its Board of Directors, effective September 10, 2021. Mr. Buckman will serve as Chair of the Company's Audit Committee and as a member of its Compensation and Nominating & Governance Committees. "Paul is a highly accomplished executive with more than 30 years of experience in the medical device sector, including senior leadership positions at some of the most well-regarded companies in the industry," said Blane Walter, Chairman of Helius' Board of Directors. "I
NEWTOWN, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced the appointment of Frederick Fantazzia to the position of Vice President of Sales & Marketing, North America, effective June 1, 2021. "Fred is a dynamic leader with 16 years of sales and marketing experience in the field of neuromodulation, and a specific focus on developing the market for new neuromodulation technologies by building and leading high-quality sales team to raise awareness and facilitate commercial adoption," said Dane Andreeff, Interim President and Chief Executive Office
WAYNE, Pa.--(BUSINESS WIRE)--Vesper Medical, Inc., a developer of medical devices for deep venous disease, today announced that Stacy Enxing Seng has joined the board of directors effective immediately. An accomplished executive leader, Stacy has over 25 years in sales, marketing and operational leadership roles building innovative technology portfolios, demonstrated clinical outcomes, exceptional management teams and world-class company cultures. She has been recognized as one of the Top 100 Women in Business and is a frequent speaker on healthcare, innovation leadership and corporate culture. She currently serves as a venture partner for Lightstone Ventures and since 2013 has a
LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, and Gyrus Capital (Gyrus), an investment firm dedicated to investments in the healthcare and sustainability sectors, today announced they have entered into an agreement whereby entities funded and controlled by Gyrus will acquire the LivaNova heart valve (HV) business. The LivaNova Board of Directors unanimously approved the divestiture, which it believes will enable the Company to sharpen its focus within its primary platforms, neuromodulation and cardiovascular, and to dedicate increased resources toward executing its promising pipeline opportunities. Once the transacti
Stifel analyst Rick Wise maintains LivaNova (NASDAQ:LIVN) with a Buy and raises the price target from $70 to $72.
Shares of G-III Apparel Group, Ltd. (NASDAQ:GIII) fell sharply during Thursday's session after the company reported worse-than-expected quarterly sales results. G-III Apparel Group posted adjusted earnings of 13 cents per share, according to data from Benzinga Pro. The company's quarterly sales came in at $609.747 million, missing market estimates of $616.286 million. G-III Apparel Group shares dipped 13.4% to $27.12 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers Virax Biolabs Group Limited (NASDAQ:VRAX) shares jumped 139.4% to $2.5390. American Oncology Network, Inc. (NASDAQ:AONC) gained 102% to $4.52. American Oncology Network expanded
Needham analyst Mike Matson reiterates LivaNova (NASDAQ:LIVN) with a Buy and maintains $72 price target.
Mizuho analyst Anthony Petrone maintains LivaNova (NASDAQ:LIVN) with a Buy and raises the price target from $75 to $80.
Baird analyst Mike Polark maintains LivaNova (NASDAQ:LIVN) with a Neutral and raises the price target from $58 to $66.
Needham analyst Mike Matson reiterates LivaNova (NASDAQ:LIVN) with a Buy and maintains $72 price target.
U.S. stocks were mixed, with the Dow Jones index gaining over 50 points on Wednesday. Shares of Powell Industries, Inc. (NASDAQ:POWL) rose sharply during Wednesday's session after the company reported better-than-expected second-quarter financial results. Powell Industries posted GAAP earnings of $2.75 per share, beating market estimates of $1.77 per share. The company's quarterly sales came in at $255.108 million versus expectations of $201.447 million, according to data from Benzinga Pro. Powell Industries shares jumped 23.2% to $176.16 on Wednesday. Here are some other big stocks recording gains in today's session. Rocky Brands, Inc. (NASDAQ:RCKY) shares jumped 31.6% to $3